Senores Pharmaceuticals Ltd. · NSE:SENORES
Senores Pharmaceuticals — Q1 FY26 Earnings Presentation
41 slides from Senores Pharmaceuticals's earnings presentation, Jul 23, 2025
Slide 1: Stock exchange intimation of investor presentation
Date: July 23, 2025 To, To, Sr. General Manager Sr. General Manager Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 BSE Sc
Slide 2: Investor Presentation July 2025
Investor Presentation July 2025
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Senores Pharmaceuticals Limited (the “Company” / “SPL”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscri
Slide 4: Financial Highlights Q1FY26
Financial Highlights Q1FY26 Private & Confidential
Slide 5: Key Highlights for the Quarter
Key Highlights for the Quarter Positive Cash Flow Strong Growth in Branded Increased Direct Stake in Operations Generics business Havix subsidiary Cash Flow from Operations Stood at Branded Generics business increased by Current stake in Havix stands at 73%as Rs. 11 Crs for Q1FY26 ~117% on Q-o-Q bas
Slide 6: Key Operational Highlights
Key Operational Highlights * Regulated Markets Emerging Markets 24 70 308 Owned Commercial ANDA Products Approved ANDA Products Approved Products 57 37 719 Pipeline Products Pipeline CGT Opportunity Products Products Under Registration 27 53 40 + CDMO/CMO Commercial Products CDMO/CMO Pipeline Produc
Slide 7: Consolidated Financial Highlights – Q1 FY26
Consolidated Financial Highlights – Q1 FY26 Income up by 72% EBIDTA up by 60% PAT up by 95% Y-o-Y for Q1 FY26 Y-o-Y for Q1 FY26 Y-o-Y for Q1 FY26 Income (Rs. Crs)* EBITDA (Rs. Crs) PAT ( Rs. Crs) 72% +15% 60% +35% 95% +18% 138.0 34.2 21.2 120.2 18.0 25.4 80.4 21.3 10.9 Q1FY25 Q4FY25 Q1FY26 Q1FY25 Q4
Slide 8: Business Segment Financial Highlights – Q1 FY26
Business Segment Financial Highlights – Q1 FY26 Regulated Markets Emerging Markets Others * +69.3% +40.1% +264.3% +21.7% +31.9% -20.5% Revenue (Rs. Crs) 90.1 36.5 18.9 29.0 15.5 64.3 53.2 22.0 5.2 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 EBIDTA Margin for Q1FY26 stood
Slide 9: Business Segment Financial Highlights – Q1 FY26
Business Segment Financial Highlights – Q1 FY26 Segment Revenue (Rs. Crs) Q1 FY25 Q4 FY25 Q1 FY26 Q-o-Q Y-o-Y Regulated Markets 53.2 64.3 90.1 40.1% 69.3% Emerging Markets 22.0 36.5 29.0 -20.5% 31.9% Branded Generics 1.8 3.8 8.2 117.9% 357.7% API 2.5 4.1 3.0 -27.0% 19.2% Other Operational Income 0.9
Slide 10: Management Commentary
Management Commentary Commenting on the Q1 FY26 performance, Mr. Swapnil Shah, Managing Director of Senores Pharmaceuticals Limited said, “Continuing the momentum from last year, we have started FY26 well, with healthy performance across segments during the quarter. We launched 2 own ANDA products i
Slide 11: Consolidated Profit & Loss Account – Q1 FY26
Consolidated Profit & Loss Account – Q1 FY26 Consolidated P&L (Rs. Crs) Q1 FY26 Q1 FY25 Y-o-Y Q4 FY25 Q-o-Q Revenue from Operations 130.3 79.5 63.9% 104.9 24.2% Other Operating Income 7.7 0.9 15.3 Total Income 138.0 80.4 71.7% 120.2 14.8% Total COGS 61.4 34.6 57.5 Gross Profit 76.6 45.8 67.4% 62.7 2
Slide 12: Update on Utilization of Funds from IPO
Update on Utilization of Funds from IPO Amount as proposed in Amount utilized as on Amount Unutilized as on Sr. No. Object as per Offer Document the Offer Document June 30, 2025 June 30, 2025 Remarks (Rs. Crs) (Rs. Crs) (Rs. Crs) Investment in one of our Subsidiaries, Havix, to fund capital expendit
Slide 13: Historical Financial Highlights
Historical Financial Highlights Private & Confidential
Slide 14: Historical Profit & Loss Account
Historical Profit & Loss Account Profit and Loss (Rs. Crs) FY25 FY24* YoY Revenue from Operations 378.0 209.0 80.9% Other Operating Income 32.4 5.6 Total Income 410.4 214.5 91.3% Total COGS 180.7 106.1 Gross Profit 229.7 108.4 111.9% Gross Margin (%) 56.0% 50.5% 540 bps Employee Cost 60.4 35.5 Other
Slide 15: Historical Balance Sheet
Historical Balance Sheet ASSETS (Rs. Crs) Mar-25 Mar-24 EQUITY AND LIABILITIES (Rs. Crs) Mar-25 Mar-24 Non-Current Assets Equity Property, Plant and Equipment 198.9 152.2 Equity Share Capital 46.1 30.5 Capital Work-in-Progress 44.2 17.8 Other Equity 740.1 173.8 Goodwill 38.2 38.2 Total Shareholder’s
Slide 16: Historical Abridged Cash Flow Statement
Historical Abridged Cash Flow Statement Cash Flow Statement (`Rs. Crs) FY25 FY24* Profit/(Loss) Before Tax 70.6 24.9 Adjustments for Non-Cash and Non-Operational Expenses / (Incomes) 27.1 17.9 Operating Profit / (Loss) Before Working Capital Changes 97.7 42.8 Changes in Working Capital -134.4 -66.1
Slide 17: About Senores Pharmaceuticals Limited
About Senores Pharmaceuticals Limited Private & Confidential
Slide 18: Introduction to Senores Pharma
Introduction to Senores Pharma Brief Overview At a Glance Global Research driven Formulation Focused company engaged in developing & manufacturing of pharmaceutical products predominantly for the Regulated Markets of the US, Canada & UK across various therapeutic areas Niche Product Identification C
Slide 19: Business Segments
Business Segments 65% 21% 14% Q1 FY26 Income Rs. 138 Crs Regulated Markets Emerging Markets Others Regulated Markets Business Emerging Markets Business Develop & manufacture pharmaceutical products for the Primarily serves the US, Canada and United Kingdom Emerging Markets USFDA approved facility in
Slide 20: Key Events & Milestones
Key Events & Milestones Consolidated presence in emerging Commenced manufacturing activities at Incorporated as “Senores markets by acquiring shares in its greenfield API plant located at Incorporated a wholly owned subsidiary, Pharmaceuticals Pvt. Ltd.” in India. Ratnatris Pharmaceuticals Pvt. Ltd.
Slide 21: Key Strengths
Key Strengths Private & Confidential
Slide 22: Key Strengths of the Company
Key Strengths of the Company 1 Distinct specialty and complex product portfolio built in a short span for Regulated Markets 2 Long-term marketing arrangements with pharmaceutical companies in the Regulated Markets 3 Presence in the Emerging Markets with portfolio, including specialty and complex pro
Slide 23: Distinct Specialty & Complex Product Portfolio Built in a Short Span
1 Distinct Specialty & Complex Product Portfolio Built in a Short Span for Regulated Markets Demonstrated Capability to propel Products from Conception to Commercialization ANDA Products Product Identification Product Development Commercial Data Analysis – IQVIA, R&D to establish API Concurrent Part
Slide 24: Presence in Regulated Markets through Long-term marketing arrangements
2 Presence in Regulated Markets through Long -term marketing arrangements MARKETED PRODUCTS CDMO / CMO Business Model Business Model Identify, Develop & Commercialize specialty & complex Customized formulation, development & manufacturing niche products in mid - market range capabilities for custome
Slide 25: Presence in the Emerging Markets with Portfolio Including Specialty and Complex Products
3 Presence in the Emerging Markets with Portfolio Including Specialty and Complex Products Special Focus Niche & Specialty patented products in the US with early launch 437 opportunity in Emerging Markets 92 South East 40+ Commonwealth of Asia Countries Sugammadex Ferric Independent Marketed States
Slide 26: Partners to Global Pharmaceutical Companies in Regulated & Emerging Markets
Partners to Global Pharmaceutical Companies in Regulated & Emerging Markets 25
Slide 27: Strong R&D Capabilities Driving Differentiated Product Portfolio
Strong R&D Capabilities Driving Differentiated Product Portfolio R&D Site 1 - USA Identify Oral Oral ▪ Internal research ORS Injectables API Solids Liquids ▪ In-House R&D in US ▪ Information available for Controlled on subscribed Substances databases R&D Site 2 - India Team ▪ Helps in dossier ▪ 64 p
Slide 28: Accredited Manufacturing Facilities
5 Accredited Manufacturing Facilities Atlanta Facility Ahmedabad, Chhatral Facility Facility 378,943 Sq. Ft. Total Area 2 Manufacturing Lines 12 185,300 Sq. Ft. Manufacturing Lines Total Area OSD 4 Dosage Forms 1.2 Bn units Annual Installed General Oral Beta Lactum Capacity Strong Regulatory Track R
Slide 29: Corporate Structure
Corporate Structure Group holding company based in India Houses Domestic Branded Generics business & API business Senores Pharmaceuticals Inc. Marketing cum ANDA Havix Group Inc Ratnatris Pharmaceuticals Pvt. Ltd. Caters to Regulated Market Caters to Emerging Market Holding Company US based company
Slide 30: Professional and Dedicated Management Team
6 Professional and Dedicated Management Team Swapnil Jatinbhai Shah Sanjay Shaileshbhai Majmudar Deval Rajnikant Shah Promoter & Managing Director Chairman & Non-Executive, Non- Whole-Time Director & CF O Independent Director ▪ 17+ years of experience in the pharma sector ▪ 40+ years of experience ▪
Slide 31: Growth Strategies
Growth Strategies Private & Confidential
Slide 32: Key Strategies
Key Strategies Inorganic growth Significantly enhance market through synergistic presence in North America & acquisitions other Regulated Markets Integrated approach by Launch products with the enhancing capabilities for potential of NDA approval in backward integration the US Strategic alliance for
Slide 33: Enhance Market Presence of Marketed Products in North America and Other Regulated Markets
Enhance Market Presence of Marketed Products in North America and Other Regulated Markets US accounts for 43% of the global pharma market, 56% of the regulated market & 91% Persistent drug shortage calls for an of North America Market increased supply of generic drugs Global pharma market by classif
Slide 34: Entering into Strategic Alliance for CMO/CDMO in Regulated Markets
Entering into Strategic Alliance for CMO/CDMO in Regulated Markets CDMO market growing faster than the pharma market Strategic alliance for CMO/CDMO in Regulated Markets which is growing at 7.7% US CDMO/CMO market (USD bn) The dependence on CDMO/CMO’s has increased as they offer 7.7% Appended Manufa
Slide 35: Expanding into New Regulated & Emerging Markets
Expanding into New Regulated & Emerging Markets Regulated & Emerging markets witnessing strong growth Global pharma market by classification (USD bn) Emerging pharma market by Product (2028F) Regulated pharma market by Product (2028F) Regulated Emerging Innovator Generic Generic Innovator 541.0 376.
Slide 36: Enhancing Capabilities for Backward Integration
Enhancing Capabilities for Backward Integration Indian API export market to grow at a CAGR of 8.4% Pursuing an integrated approach for greater backward integration API exports (USD bn) Setup Greenfield unit - Increase API manufacturing capacity CAGR: 8.4% Proposed from 25 MTPA to 169 MTPA 7.1 Expans
Slide 37: Industry Overview
Industry Overview Private & Confidential
Slide 38: Global Pharma Market
Global Pharma Market Global pharma market is expected to grow at …regulated market will continue to dominate the US continues to exert influence on Global pharma market 6.6% from 2023-28… global pharma market Global pharma market by product type (USD bn) Global pharma market by region (USD bn) Share
Slide 39: Regulated Pharma Market
Regulated Pharma Market Regulated markets to dominate the global pharmaceutical sector, driven by their access to a growing innovative drug market & a thriving generics market Regulated markets constitute 77% of the global North America accounts for 62% of regulated New generics and patent expiratio
Slide 40: Emerging Pharma Market
Emerging Pharma Market Emerging pharma market Overview of India pharma market Emerging markets to outpace developed ones… IPM is amongst the fastest growing in the Oral solids will dominate IPM world… Emerging pharma market size (USD bn) Indian pharma market size (USD bn) Indian pharma market by dos
Slide 41: Senores Pharmaceuticals Limited – Contact Us
SENORES PHARMACEUTICALS LIMITED CONTACT US Senores Pharmaceuticals Limited Strategic Growth Advisors Private Limited CIN: L24290GJ2017PLC100263 CIN: U74140MH2010PTC204285 Mr. Deval Shah – Whole Time Director & CFO Mr. Sagar Shroff / Mr. Tanay Shah sagar.shroff@sgapl.net / tanay.shah@sgapl.net +91 98
Senores Pharmaceuticals — Q1 FY26 Earnings Presentation on 6ix